Measles-Mumps-Rubella (MMR) Vaccine – Priorix

Lynn Bahta RN, MPH

Chair, ACIP MMR Vaccine Work Group

June 23, 2022

Background

- **Food and Drug Administration (FDA) approved the MMR vaccine manufactured by GSK as Priorix in June 2022**
- **Previously, only one licensed MMR vaccine in the United States (M-M-R II manufactured by Merck)**
- **Current MMR vaccine recommendations:**
  - On label uses[1]
    - ≥ 12 months for prevention of measles, mumps, and rubella
    - Measles post-exposure prophylaxis
  - Off label uses
    - ≥ 6 – 12 months for persons planning to travel or live abroad or during outbreaks[1]
    - 3rd dose for persons previously vaccinated with 2 doses who are identified as being at increased risk because of a mumps outbreak[2]
- **MMR Vaccine Work Group formed in January 2022 to evaluate safety and immunogenicity of Priorix as compared to M-M-R II**

[1] https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6204a1.htm
[2] https://www.cdc.gov/mmwr/volumes/67/wr/mm6701a7.htm

Work Group Members and Participants

- **ACIP members**
  - Lynn Bahta (chair)
  - Jamie Loehr

Ex-officio/government members
- FDA: Robin Wisch
- FDA: Nadine Peart

Liaisons
- AAFP: Laura Morris
- AAP: Adam Ratner
- AIM: Juventila Liko
- NAPNAP: Patsy Stinchfield

- **CDC Lead**
  - Elisabeth Krow-Lucal

- **CDC Participants**
  - Kathleen Dooling
  - Mona Marin
  - Paul Gastanaduy
  - Paul Rota
  - Tatiana Lanzieri
  - Satoshi Kamidani
  - Andrew Kroger
  - Stephen Crooke
  - Leah Shepersky

Overview of previous Work Group presentations to ACIP and today's session

- **February 2022**
  - Presentation of data by GSK on safety and immunogenicity of Priorix as compared to M-M-R II

- **June 2022**
  - Evidence to Recommendations Framework
  - Literature review
  - Proposed recommendations